Related Experiment Video
Updated: May 18, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Small cell bladder cancer: biology and management
Elie Fahed1, Donna E Hansel, Derek Raghavan
1University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Seminars in Oncology
|October 9, 2012
Summary
Small cell bladder cancer (SCBC) is aggressive, often requiring surgery and chemotherapy for better survival. Understanding SCBC
Area of Science:
- Oncology
- Urothelial Carcinomas
Background:
- Small cell bladder cancer (SCBC) is a rare, aggressive malignancy.
- SCBC shares biological traits with small cell lung carcinoma.
- Untreated SCBC has a poor prognosis.
Purpose of the Study:
- To review current treatment strategies for SCBC.
- To highlight the role of systemic therapy in improving survival.
- To emphasize the need for understanding molecular drivers for new therapies.
Main Methods:
- Review of published literature on SCBC treatment.
- Analysis of common chemotherapy regimens (platinum/etoposide, doxorubicin-based).
- Discussion of surgical and systemic therapy approaches.
Main Results:
- Surgery is a mainstay but often insufficient alone.
- Systemic chemotherapy, particularly platinum/etoposide, improves survival.
- Metastatic SCBC has a poor prognosis with median survival <= 18 months.
Conclusions:
- SCBC necessitates multimodal treatment including surgery and chemotherapy.
- Current therapies offer survival benefits but relapse is common.
- Further research into SCBC molecular alterations is crucial for novel therapeutic strategies.
